Mainstream

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Post ContentxgnRead More

You might also be interested in reading Bittensor (TAO) To Lead The ‘AI Wave’: Analysts Bullish Despite 10% Price Drop.

July 29, 2025
In Mainstream